Eisai, DNAVEC Join in Drug Discovery Research for Alzheimer's Disease.Tokyo, Japan, Mar 31, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Eisai has signed an agreement with DNAVEC on drug discovery research for Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. (AD). Under the agreement, the two companies aim to develop a vaccine therapy vaccine therapy A therapeutic strategy to boost the immune response against a particular pathogen to such degree that the vaccine alone is enough to treat the Pt for AD. Specifically, using DNAVEC's proprietary Sendai virus vector, they plan to develop a gene vaccine that can selectively induce the production of anti-beta amyloid amyloid /am·y·loid/ (am´i-loid) 1. starchlike; amylaceous. 2. the pathologic, extracellular, waxy, amorphous substance deposited in amyloidosis, being composed of fibrils in bundles or in a meshwork of polypeptide antibodies. Beta amyloid is considered to play a role in preventing and suppressing the progress of AD. Eisai has a prior right to develop, manufacture and sell results obtained from the partnership. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion